Revenue
2022
2023
2024
2025
AtaiBeckley Inc. (ATAI)
Price$7.39Cached quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $4.1M | $308,000 | $314,000 | $233,000 |
| Research & development | $53.1M | $55.5M | $62.2M | $74.3M |
| Operating expenses | $648.1M | $103.0M | $123.3M | $144.7M |
| Operating income | −$644.1M | −$102.7M | −$123.0M | −$144.4M |
| Operating margin | −15,751.06% | −33,341.23% | −39,180.25% | −61,987.12% |
| EBITDA | −$643.0M | −$102.2M | −$36.3M | −$134.1M |
| EBITDA margin | −15,726.31% | −33,187.66% | −11,564.01% | −57,549.79% |
| Net income | −$660.0M | −$149.3M | −$40.2M | −$152.4M |
| Net profit margin | −16,142.02% | −48,463.96% | −12,810.19% | −65,401.29% |
| Basic EPSper basic share | -$2.91 | -$0.93 | -$0.25 | -$0.98 |
| Diluted EPSper diluted share | -$2.91 | -$0.93 | -$0.25 | -$0.98 |
Owners
Reported shareholders
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 26, 2026Form 4 · 10b5-1 | Kochendoerfer GerdChief Operating Officer | SellCommon Stock | 50.0K | $5.00 | $250.0K | 0 |
| Jun 25, 2026Form 4 · 10b5-1 | Craig Kevin JamesChief Medical Officer | SellCommon Stock | 42.6K | $4.51 | $192.0K | 8.4K |
| Apr 20, 2026Form 4 · 10b5-1 | Craig Kevin JamesChief Medical Officer | SellCommon Stock | 42.6K | $5.00 | $212.9K | 8.4K |
| Mar 20, 2026Form 4 · 10b5-1 | Craig Kevin JamesChief Medical Officer | SellCommon Stock | 100.0K | $3.55 | $355.0K | 8.4K |
| Jan 2, 2026Form 4 | Feilding-Mellen CosmoDirector | SellCommon Stock | 39.6K | $3.90 | $154.4K | 7.66M |